Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature

被引:2
作者
Karvigh, Sanaz Ahmadi [1 ]
Salehizadeh, Saeideh [1 ]
Vahabizad, Fahimeh [1 ]
机构
[1] Univ Tehran Med Sci, Sina Hosp, Dept Neurol, Tehran, Iran
关键词
LGI1; Faciobrachial dystonic seizure (FBDS); Basal ganglia; Immunotherapy; Rituximab; Autoimmune encephalitis; FACIOBRACHIAL DYSTONIC SEIZURES; LGI1; IMMUNOTHERAPY; ANTIBODIES; RITUXIMAB; THERAPY; CASPR2;
D O I
10.1186/s13256-022-03650-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Anti-leucine-rich glioma-inactivated 1 encephalitis is a newly emerged entity characterized by frequent faciobrachial dystonic seizures and a wide spectrum of subacute clinical symptoms such as other seizure types, mood and behavioral changes, and memory loss. We should be aware of differentiating this diagnosis from psychogenic nonepileptic seizures. Mesial temporal, limbic structures, and basal ganglia are the most commonly involved regions. Case presentation Here we review the available data, and report on two young Iranian (White) females, 24 and 18 years old, who represent distinct aspects of the disease. The clinical presentation and degree of tissue involvement varies to some extent in the two reported cases. Case 1 had prominent neuropsychiatric symptoms and suffered from frequent faciobrachial dystonic seizures with more significant basal ganglia involvement, whereas case 2 suffered from severe memory decline and dialeptic seizures along with mesial temporal involvement. Symptoms were refractory to usual treatment and prompt immunotherapy was needed. Conclusions This disease has a rather favorable outcome provided that treatment is initiated early. However, resistance to first-line treatment, relapses, and long-term complications highlight the need to establish reliable biomarkers to distinguish different subtypes of this disorder to predict the clinical outcome and prognosis, and to refine management.
引用
收藏
页数:8
相关论文
共 27 条
[21]   Natural course of LGI1 encephalitis: 3-5 years of follow-up without immunotherapy [J].
Szots, Monika ;
Marton, Annamaria ;
Kover, Ferenc ;
Kiss, Tunde ;
Berki, Timea ;
Nagy, Ferenc ;
Illes, Zsolt .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 343 (1-2) :198-202
[22]   The importance of early immunotherapy in patients with faciobrachial dystonic seizures [J].
Thompson, Julia ;
Bi, Mian ;
Murchison, Andrew G. ;
Makuch, Mateusz ;
Bien, Christian G. ;
Chu, Kon ;
Farooque, Pue ;
Gelfand, Jeffrey M. ;
Geschwind, Michael D. ;
Hirsch, Lawrence J. ;
Somerville, Ernest ;
Lang, Bethan ;
Vincent, Angela ;
Leite, Maria I. ;
Waters, Patrick ;
Irani, Sarosh R. .
BRAIN, 2018, 141 :348-356
[23]   From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time [J].
van Sonderen, A. ;
Schreurs, M. W. J. ;
Wirtz, P. W. ;
Smitt, P. A. E. Sillevis ;
Titulaer, M. J. .
AUTOIMMUNITY REVIEWS, 2016, 15 (10) :970-974
[24]   The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis [J].
van Sonderen, Agnes ;
Petit-Pedrol, Mar ;
Dalmau, Josep ;
Titulaer, Maarten J. .
NATURE REVIEWS NEUROLOGY, 2017, 13 (05) :290-301
[25]  
van Sonderen A, 2016, NEUROLOGY, V87, P1449
[26]  
VANAMELSVOORT T, 1994, EPILEPSIA, V35, P181
[27]   Rituximab associated neutropenia: Description of three cases and an insight into the underlying pathogenesis [J].
Weissmann-Brenner, Alina ;
Brenner, Baruch ;
Belyaeva, Inessa ;
Lahav, Meir ;
Rabizadeh, Esther .
MEDICAL SCIENCE MONITOR, 2011, 17 (11) :CS133-CS137